Interaction of Apelin and Angiotensin in the Human Forearm Circulation

Sponsor

University of Edinburgh (Other)

Overall Status

Completed

CT.gov ID

NCT00901745

Collaborator

(none)

Enrollment

Location

Arms

Duration (Months)

1.1

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The apelin-APJ system is a relatively new discovery. It has generated interest in part due to it's apparent ability to counteract the renin-angiotensin system, which is frequently overactive in many cardiovascular disease.

Apelin has the ability to cause blood vessels to relax, increasing their diameter and hence blood flow down the blood vessel. The researchers wish to investigate the hypothesis that an infusion of apelin will reduce the effects of angiotensin II, which is know to reduce the diameter of blood vessels.

Condition or Disease	Intervention/Treatment	Phase
Heart Disease Vasodilation	Drug: Angiotensin II Drug: Noradrenaline infusion	N/A

Study Design

Study Type:

Interventional

Anticipated Enrollment :

12 participants

Allocation:

Randomized

Intervention Model:

Crossover Assignment

Masking:

Double (Participant, Investigator)

Primary Purpose:

Basic Science

Official Title:

Investigating the Interaction of Apelin and Angiotensin II Peripheral Resistance Vessels in Vivo in Man

Study Start Date :

May 1, 2009

Actual Primary Completion Date :

Apr 1, 2010

Actual Study Completion Date :

Apr 1, 2010

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Infusion of apelin Using forearm venous occlusion plethysmography apelin will be infused to cause reduction in forearm blood flow. Infusion of angiotensin II and noradrenaline will given and vasoconstriction will be assessed. Blood samples for the infused arm and contra-lateral arm will be taken at regular time points to assess local and systemic changes in relevant hormones.	Drug: Angiotensin II Infusion of up to 30picmol/ml angiotensin II will be infused and respondent vasoconstriction assessed. Drug: Noradrenaline infusion Infusion of up to 480 picomol/ml of noradrenaline will be infused.
Active Comparator: Sodium nitroprusside infusion Using forearm venous occlusion plethysmography sodium nitroprusside will be infused to cause reduction in forearm blood flow. Infusion of angiotensin II and noradrenaline will given and vasoconstriction will be assessed. Blood samples for the infused arm and contra-lateral arm will be taken at regular time points to assess local and systemic changes in relevant hormones.	Drug: Angiotensin II Infusion of up to 30picmol/ml angiotensin II will be infused and respondent vasoconstriction assessed. Drug: Noradrenaline infusion Infusion of up to 480 picomol/ml of noradrenaline will be infused.

Arm

Intervention/Treatment

Experimental: Infusion of apelin

Using forearm venous occlusion plethysmography apelin will be infused to cause reduction in forearm blood flow. Infusion of angiotensin II and noradrenaline will given and vasoconstriction will be assessed. Blood samples for the infused arm and contra-lateral arm will be taken at regular time points to assess local and systemic changes in relevant hormones.

Drug: Angiotensin II

Infusion of up to 30picmol/ml angiotensin II will be infused and respondent vasoconstriction assessed.

Drug: Noradrenaline infusion

Infusion of up to 480 picomol/ml of noradrenaline will be infused.

Active Comparator: Sodium nitroprusside infusion

Using forearm venous occlusion plethysmography sodium nitroprusside will be infused to cause reduction in forearm blood flow. Infusion of angiotensin II and noradrenaline will given and vasoconstriction will be assessed. Blood samples for the infused arm and contra-lateral arm will be taken at regular time points to assess local and systemic changes in relevant hormones.

Drug: Angiotensin II

Infusion of up to 30picmol/ml angiotensin II will be infused and respondent vasoconstriction assessed.

Drug: Noradrenaline infusion

Infusion of up to 480 picomol/ml of noradrenaline will be infused.